Early steps of microglial activation are directly affected by neuroprotectant FK506 in both in vitro inflammation and in rat model of stroke
Open Access
- 18 July 2012
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 90 (12) , 1459-1471
Abstract
Neuroprotective and/or neuroregenerative activity of FK506, its derivatives, and to a lesser extent cyclosporin A (CsA) in animal models of neurodegenerative diseases of different etiology have been reported. Here, we verified a hypothesis that the most likely mechanism of their neuroprotective action is inhibition of the early steps of inflammatory activation of microglia by interference with mitogen-activated protein kinase (MAPK) signaling. The effect of immunosuppressants on lipopolysaccharide (LPS)-induced changes in morphology, proliferation, and motility of rat primary microglial cultures was evaluated. FK506 and CsA directly inhibited LPS-induced microglia activation and inflammatory responses. While both drugs efficiently reduced the expression of iNOS and the release of nitric oxide, only FK506 strongly inhibited the expression of Cox-2 and secretion of the mature form of IL-1β. FK506 strongly reduced LPS-induced activation of MAPK, and its downstream signaling crucial for inflammatory responses. Comparative analysis of global gene expression in rat ischemic brains and in LPS-stimulated microglial cultures revealed many genes and signaling pathways regulated in the same way in both systems. FK506 treatment blocked a majority of genes induced by an ischemic insult in the cortex, in particular inflammatory/innate immunity and apoptosis-related genes. Microglia-mediated inflammation is considered as one of the most important components of brain injury after trauma or stroke; thus, effective and multifaceted blockade of microglial activation by FK506 has clinical relevance and potential therapeutic implications.Keywords
This publication has 35 references indexed in Scilit:
- Interleukin-1 and Stroke: Biomarker, Harbinger of Damage, and Therapeutic TargetCerebrovascular Diseases, 2011
- MAPK Signal Transduction Underlying Brain Inflammation and Gliosis as Therapeutic TargetThe Anatomical Record, 2009
- FK506 Protects Against Various Immune Responses and Secondary Degeneration Following Cerebral IschemiaThe Anatomical Record, 2009
- Interleukin-1 and neuronal injuryNature Reviews Immunology, 2005
- Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental StrokeJournal of Cerebral Blood Flow & Metabolism, 2005
- A novel mechanism of FK506‐mediated neuroprotection: Downregulation of cytokine expression in glial cellsGlia, 2004
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences, 2003
- Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanismsBritish Journal of Pharmacology, 1999
- Tacrolimus (FK506) Attenuates Leukocyte Accumulation After Transient Retinal IschemiaStroke, 1998